Policy & Regulation
FDA Schedules July Review That Could Reshape the Research Peptide Landscape
A federal advisory review puts peptide compounding policy, research access, and regulatory oversight into sharper focus.
Department
Policy & Regulation
Reporting and analysis from the Research Pep News inaugural archive.
Policy & Regulation
FDA Panel to Review Broader Access to Certain Peptides
A closer look at the advisory process, the compounds under discussion, and what a policy recommendation can—and cannot—change.
Policy & Regulation
RFK Jr. Says He’s a ‘BIG FAN’ of Peptide Injections – Pushes for Deregulation
Comments from the nation’s health secretary add political momentum to an already active regulatory debate.
Policy & Regulation
FDA Faces Pressure to Ease Access to Peptides
Advocates, clinicians, regulators, and industry participants are pressing competing cases over access and oversight.
Policy & Regulation
Update: Peptide Legislation, FDA Regulation, and RFK Jr.’s Role in the 2026 Peptide Debate
A research-focused update on federal policy, compounding reviews, access arguments, and the political figures shaping the debate.
Policy & Regulation
Peptide Policy Is Entering a New Era: Why 2026 Could Bring More Clarity, Broader Access, and Better Research Standards
A changing policy conversation may bring clearer distinctions among approved medicines, compounded preparations, and investigational compounds.